Plain-English translation of NCT06914648 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a study for patients with primary liver cancer who need surgery but don't currently have enough healthy liver remaining to safely have the operation. The trial compares two preparation approaches: portal vein embolization (PVE) alone, which is the current standard, versus combined portal and hepatic vein embolization (PVE/HVE), which is a newer method. Both approaches involve blocking blood vessels to encourage the remaining liver to grow before surgery.
Most liver cancer patients are diagnosed too late for immediate surgery. Many need their remaining liver to grow first to safely survive the operation, but about 1 in 4 patients don't grow enough liver with the current treatment alone. This trial tests whether blocking an additional vein helps more patients' livers grow enough so they can have surgery and improve their chances of survival.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the standard vein-blocking procedure alone or the new combined procedure. Both approaches use minimally invasive techniques where doctors guide a catheter through your blood vessels to block the targeted veins. After the procedure, your liver will be monitored over weeks to see how much it grows. Once your liver has grown enough, you will proceed to surgery to remove the cancer.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States